Lu Zhou

Lu Zhou


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in Advanced Science
Verified
Journal Article
Open access
YZYimin Zheng
Yimin Zheng
YWYining Wang
Yining Wang
ZLZhou Lu
Zhou Lu
JWJinkai Wan
Jinkai Wan
LJLulu Jiang
Lulu Jiang
JCJia-Bin Cai
Jia-Bin Cai
The combination of immunotherapy and molecular targeted therapy exhibits promising therapeutic efficacy in hepatocellular carcinoma (HCC), but the underlying mechanism is still unclear. Here, phosphoglycerate mutase 1 (PGAM1) is identified as a novel immunometabolic target by using a bioinformatic algorithm based on multiple HCC datasets. PGAM1 is highly expressed in HCC and associated with a poor prognosis and a poor response to immunotherapy. In vitro and in vivo experiments indicate that targeting PGAM1 inhibited HCC cell growth and promoted the infiltration of CD8+ T‐cells due to decreased enzymatic activity. Mechanistically, inhibition of PGAM1 promotes HCC cell ferroptosis by downregulating Lipocalin (LCN2) by inducing energy stress and ROS‐dependent AKT inhibition, which can also downregulate Programmed death 1‐ligand 1 (PD‐L1). Moreover, an allosteric PGAM1 inhibitor (KH3) exhibits good antitumor effects in patient‐derived xenograft (PDX) models and enhanced the efficacy of anti‐PD‐1 immunotherapy in subcutaneous and orthotopic HCC models. Taken together, the findings demonstrate that PGAM1 inhibition exerts an antitumor effect by promoting ferroptosis and CD8+ T‐cell infiltration and can synergize with anti‐PD‐1 immunotherapy in HCC. Targeting PGAM1 can be a promising new strategy of “killing two birds with one stone” for HCC treatment.

1 December 2019 in Cell Metabolism
Verified
Journal Article
Closed access
KHKe Huang
Ke Huang
QLQian Liang
Qian Liang
YZYe Zhou
Ye Zhou
LJLu-Lu Jiang
Lu-Lu Jiang
WGWei-Ming Gu
Wei-Ming Gu
YSYing Shen
Ying Shen

19 October 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
LJLulu Jiang
Lulu Jiang
SLSixiu Liu
Sixiu Liu
XJXinglong Jia
Xinglong Jia
QGQinting Gong
Qinting Gong
XWXin Wen
Xin Wen
LZLu Zhou
Lu Zhou

29 October 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CWChen-Lei Wen
Chen-Lei Wen
KHKe Huang
Ke Huang
LJLu-Lu Jiang
Lu-Lu Jiang
XLXiong-Xiong Lu
Xiong-Xiong Lu
YDYu-Ting Dai
Yu-Ting Dai
LZLu Zhou
Lu Zhou
Glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) plays a critical role in cancer metabolism by coordinating glycolysis and biosynthesis. A well-validated PGAM1 inhibitor, however, has not been reported for treating pancreatic ductal adenocarcinoma (PDAC), which is one of the deadliest malignancies worldwide. By uncovering the elevated PGAM1 expressions were statistically related to worse prognosis of PDAC in a cohort of 50 patients, we developed a series of allosteric PGAM1 inhibitors by structure-guided optimization. The compound KH3 significantly suppressed proliferation of various PDAC cells by down-regulating the levels of glycolysis and mitochondrial respiration in correlation with PGAM1 expression. Similar to PGAM1 depletion, KH3 dramatically hampered the canonic pathways highly involved in cancer metabolism and development. Additionally, we observed the shared expression profiles of several signature pathways at 12 h after treatment in multiple PDAC primary cells of which the matched patient-derived xenograft (PDX) models responded similarly to KH3 in the 2 wk treatment. The better responses to KH3 in PDXs were associated with higher expression of PGAM1 and longer/stronger suppressions of cancer metabolic pathways. Taken together, our findings demonstrate a strategy of targeting cancer metabolism by PGAM1 inhibition in PDAC. Also, this work provided “proof of concept” for the potential application of metabolic treatment in clinical practice.

15 November 2024 in Science
Verified
Journal Article
Closed access
YLYi Lu
Yi Lu
CYChen-Xi Yue
Chen-Xi Yue
LZLi Zhang
Li Zhang
DYDeqiang Yao
Deqiang Yao
YXYing Xia
Ying Xia
YCYu Cao
Yu Cao
Precise regulation of intracellular phosphate (Pi) is critical for cellular function, with xenotropic and polytropic retrovirus receptor 1 (XPR1) serving as the sole Pi exporter in humans. The mechanism of Pi efflux, activated by inositol pyrophosphates (PP-IPs), has remained unclear. This study presents cryo–electron microscopy structures of XPR1 in multiple conformations, revealing a transmembrane pathway for Pi export and a dual-binding activation pattern for PP-IPs. A canonical binding site is located at the dimeric interface of Syg1/Pho81/XPR1 (SPX) domains, and a second site, biased toward PP-IPs, is found between the transmembrane and SPX domains. By integrating structural studies with electrophysiological analyses, we characterized XPR1 as an inositol phosphates (IPs)/PP-IPs–activated phosphate channel. The interplay among its transmembrane domains, SPX domains, and IPs/PP-IPs orchestrates the conformational transition between its closed and open states.

25 October 2022 in Environment International
Verified
Journal Article
Open access
LZLu Zhou
Lu Zhou
CHCheng He
Cheng He
HKHo Kim
Ho Kim
Yasushi HondaYasushi Honda
Yasushi Honda
WLWhanhee Lee
Whanhee Lee
Haidong KanHaidong Kan
Haidong Kan
Stroke is a leading cause of death and disability in East Asia. Owing to the aging population and high prevalence of stroke, East Asia might suffer a disproportionately heavy burden of stroke under the changing climate. However, the evidence relevant is still limited in this area. To evaluate the stroke mortality risk due to heat exposure in East Asia and predict its burden under various future climate change scenarios. We conducted a multi-center observational study and collected data from 22 representative cities in three main East Asian countries (i.e., China, Japan, and South Korea) from 1972 to 2015. The two-stage time-series analyses were applied to estimate the effects of heat on stroke mortality at the regional and country level. We further projected the burden of heat-related stroke mortality using 10 global climate models (GCMs) under four shared socioeconomic pathway and representative concentration pathway (SSP-RCP) scenarios, including SSP1-RCP1.9, SSP1-RCP2.6, SSP2-RCP4.5, and SSP5-RCP8.5 scenarios. In the present study, a total of 287,579 stroke deaths were collected during the warm season. Heat was significantly associated with an increased risk of stroke mortality. Overall, compared with the 2010 s, the heat-related attributable fraction (AF) was projected to increase in the 2090 s, with increments ranging from 0.8 % to 7.5 % across various climate change scenarios. The heat-related AF was projected to reach 11.9 % (95 % empirical confidence interval [eCI]: 6.1 %, 17.5 %) in the 2090 s under the SSP5-RCP8.5 scenario in China, while the corresponding estimates were 6.6 % (95 % eCI: 2.5 %, 11.0 %) and 5.1 % (95 % eCI: 1.2 %, 9.1 %) for Japan and South Korea, respectively. Climate change will exacerbate the burden of heat-related stroke mortality but with considerable geographical heterogeneity in East Asia.